Delta-Fly Pharma, Inc. Logo

Delta-Fly Pharma, Inc.

Develops innovative, gentle anticancer agents with reduced side effects for cancer patients.

4598 | T

Overview

Corporate Details

ISIN(s):
JP3549370009
LEI:
Country:
Japan
Address:
徳島市川内町宮島錦野37番地の5
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the research and development of anticancer agents. The company utilizes its proprietary "Module Drug Development" concept to create innovative and "gentle" cancer treatments designed to have reduced side effects and be available at a reasonable price. Its development pipeline focuses on small molecule and RNA therapeutics for various cancers, including Acute Myeloid Leukemia. Delta-Fly Pharma's mission is to develop medicines that benefit cancer patients and society through its unique drug discovery approach.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:39
Interim Report
確認書
Japanese 8.9 KB
2025-11-14 07:35
Interim Report
半期報告書-第16期(2025/04/01-2026/03/31)
Japanese 206.9 KB
2025-06-27 08:44
Post-Annual General Meeting Information
臨時報告書
Japanese 24.4 KB
2025-06-27 08:39
Governance Information
内部統制報告書-第15期(2024/04/01-2025/03/31)
Japanese 23.0 KB
2025-06-27 08:34
Registration Form
確認書
Japanese 8.8 KB
2025-06-27 08:30
Registration Form
有価証券報告書-第15期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2025-04-14 08:30
Prospectus
有価証券届出書(組込方式)
Japanese 289.0 KB
2024-11-14 07:39
Interim Report
確認書
Japanese 8.9 KB
2024-11-14 07:36
Interim Report
半期報告書-第15期(2024/04/01-2025/03/31)
Japanese 180.2 KB
2024-10-07 08:00
Major Shareholding Notification
臨時報告書
Japanese 22.6 KB
2024-09-20 08:00
Registration Form
有価証券届出書(組込方式)
Japanese 326.2 KB
2024-09-11 08:00
Major Shareholding Notification
臨時報告書
Japanese 22.8 KB
2024-06-28 08:31
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2024-06-28 08:28
Registration Form
確認書
Japanese 8.8 KB
2024-06-28 08:25
Governance Information
内部統制報告書-第14期(2023/04/01-2024/03/31)
Japanese 22.6 KB

Automate Your Workflow. Get a real-time feed of all Delta-Fly Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Delta-Fly Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Delta-Fly Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.